Program Description
The keynote address to PTCE's 2025 Lymphoma Day of Education offers oncology pharmacists a crucial foundation in the evolving pharmacologic landscape of non-Hodgkin lymphoma (NHL) therapies. A thorough understanding of oncology pharmacology is paramount for pharmacists to optimize patient outcomes, mitigate adverse effects, and ensure the safe and effective use of complex therapeutic regimens. Using animation videos, this session will delve into the intricate mechanisms of action and therapeutic targets of novel agents, providing a deeper understanding of how these treatments combat NHL. Attendees will gain essential knowledge to differentiate the unique toxicity profiles, monitoring parameters, and supportive care strategies across various novel therapeutic classes. Furthermore, the address will equip pharmacists with practical insights into agent-specific administration routes, optimal dosing strategies, and critical clinical considerations for seamlessly integrating these innovative NHL therapies into practice.
Target Audience: Oncology Pharmacist
Type of Activity: Application
Release date: September 30, 2025
Expiration date: September 30, 2026
Learner level: Foundational, Intermediate, Advanced
Time to complete activity: 1.25 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Describe the mechanisms of action and therapeutic targets of novel agents used in the treatment of non-Hodgkin lymphoma (NHL)
- Recognize the unique toxicity profiles, monitoring parameters, and supportive care strategies for novel therapeutic classes used in the treatment of NHL
- Review agent-specific administration routes, dosing strategies, and clinical considerations for integrating novel NHL therapies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here